Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2007-07-04
2010-11-23
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S291000, C514S352000, C514S368000, C514S370000, C514S400000, C514S471000
Reexamination Certificate
active
07838513
ABSTRACT:
The present invention relates to the treatment of a mammal with a pharmaceutical composition comprising an H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and, optionally, levamisole, a retinoid, an NFkB inhibitor, a redox quinone, an agent that enhances the intracellular accumulation of NADH+H+, a poly-alcohol, an inhibitor of pro-angiogenic growth factor(s) and an MMP inhibitor, such pharmaceutical composition allowing for the enhanced therapy and/or prevention of neoplastic diseases and disorders.
REFERENCES:
patent: 2003/0158118 (2003-08-01), Weidner
patent: 2005/0148521 (2005-07-01), Ben-Sasson et al.
patent: 0584001 (1994-02-01), None
patent: 0584001 (1994-02-01), None
patent: 11228409 (1999-08-01), None
patent: 03/061566 (2003-07-01), None
patent: 2005/076987 (2005-08-01), None
patent: 2006/056889 (2006-06-01), None
patent: WO 2006/056889 (2006-06-01), None
Sarloos, et al., Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis, Clin. Exp. Metastasis, 1993, vol. 11, 275-283.
Collins, et al., Histamine Receptor Antagonism and Anti-Tumour Activity, Br. J. Cancer, 1982, vol. 46, 817-820.
Natori, et al., Cimetidine inhibits angiogenesis and suppresses tumor growth, Biomedicine & Pharmacotherapy, 2005, vol. 59, 56-60.
Tetef, et al., Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial, J. Cancer Res Clin Oncol, 1995, vol. 121: 103-106.
Duffy, et al., Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-steroidal Anti-inflammatory Drugs (NSAIDs), European Journal of Cancer, 1998, vol. 34, No. 8, 1250-1259.
Saito, et al., All-trans Retinoic Acid Induces in Vitro Angiogenesis via Retinoic Acid Receptor: Possible Involvement of Paracrine Effects of Endogenous Vascular Endothelial Growth Factor Signaling, Endocrinology, 2007, vol. 148, No. 3, 1412-1423.
Powis, Free Radical Formation by Antitumor Quinones, Free Radical Biology & Medicine, 1989, vol. 6, 63-101.
DeVita, et al., Cancer: Principles and Practice of Oncology, 5th Edition, 1171-1175.
Henley, III Raymond J
Nixon & Peabody LLP
Tiltan Pharma Ltd.
LandOfFree
Anti-cancer therapy comprising an H2-blocker, at least one... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cancer therapy comprising an H2-blocker, at least one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer therapy comprising an H2-blocker, at least one... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4193163